Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Bristol-Myers Squibb
Celeste Lebbé; Nicolas Meyer; Laurent Mortier; Ivan Marquez-Rodas; Caroline Robert; Piotr Rutkowski; Alexander M Menzies; Thomas Eigentler; Paolo A Ascierto; Michael Smylie; Dirk Schadendorf; Mazhar Ajaz; Inge Marie Svane; Rene Gonzalez; Linda Rollin; Jennifer Lord-Bessen; Abdel Saci; Elena Grigoryeva; Jacopo Pigozzo